van Houtum, William
Schrömbges, Patrick
Amadid, Hanan http://orcid.org/0000-0001-5759-4960
van Bon, Arianne C. http://orcid.org/0009-0003-9459-8321
Braae, Uffe C. http://orcid.org/0000-0002-2743-4584
Hoogstraten, Charlotte http://orcid.org/0009-0005-4262-7420
Herrings, Hans
Clinical trials referenced in this document:
Documents that mention this clinical trial
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study
https://doi.org/10.1007/s13300-024-01588-5
Funding for this research was provided by:
Novo Nordisk A/S
Article History
Received: 6 February 2024
Accepted: 11 April 2024
First Online: 11 June 2024
Declarations
:
: William van Houtum and Patrick Schrömbges are National Leaders of PIONEER REAL Netherlands. Hanan Amadid, Uffe C. Braae and Charlotte Hoogstraten are employees of, and shareholders in, Novo Nordisk A/S. Arianne C. van Bon has been a speaker at various training courses and conferences (sponsored and not sponsored) and a speaker for medical companies including Novo Nordisk. Hans Herrings was sponsored by Novo Nordisk to organise, collect data for and advise on, the PIONEER REAL Netherlands study.
: The study protocol was approved by appropriate health authorities according to local guidelines and by an institutional review board/independent ethics committee. The ethics committee was The Dutch Clinical Research Foundation for all study sites. The study was conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments and International Council for Harmonisation (ICH) Good Clinical Practice guidelines. Participants provided written informed consent prior to commencement of any study-related activity.